. 2003 Apr;89(4):451–458. doi: 10.1136/heart.89.4.451

Table 6.

Non-statin based trials in subjects with coronary heart disease: angiographic trials confirming reduced CAD progression

	Treatments	Duration
Finnish regression study (1983)^w37	Clofibrate + nicotinic acid	7 years

NHLBI coronary intervention study (1984)^w38	Cholestyramine	5 years

Cholesterol Lowering Atherosclerosis Study (CLAS I) (1987)^w39, (CLAS II) (1990)^w40	Nicotinic acid + colestipol	2 years, 4 years

St Thomas’ Atherosclerosis Study (STARS) (1992)^w9	Cholestyramine	3 years

Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) (1996)^w41	Bezafibrate	5 years

Lopid Coronary Angiography Trial (LOCAT) (1997)^w42	Gemfibrozil	2.6 years

Diabetes Atherosclerosis Intervention Study (DAIS) (2001)^w43	Fenofibrate	3 years

Baseline mean cholesterol 5.4–8.0 mmol/l.

Lipid reduction: Cholesterol −9% to −27%, triglyceride −18% to −40%.